Understanding Alzheimer’s and developing treatments

Alzheimer’s disease is the major cause of dementia with nearly 40 million sufferers globally and no known cure. The Diagnostic and Drug Discovery Initiative for Alzheimer's Disease (D3i4AD) consortium is an EU-FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) project which aims to develop chemical biology tools to better understand the role of prion protein in Alzheimer’s disease and to harness this understanding to develop new chemical compounds for diagnostic and therapeutic applications. The consortium partners are the University of Sheffield (Information School and the Department of Chemistry), the University of Lisbon, the University of Bari, Eli Lilly and Biofordrug.

Our role in the project is to apply chemoinformatics tools to model the interactions between prion and its binding partners including amyloid-b, BACE, Fyn, Cav-1 and Tau and to identify small molecules that can perturb those interactions.

More details can be found on the project's website.